REVERSING EPITHELIAL TO MESENCHYMAL TRANSITION BY TARGETED EPIGENETIC EDITING IN BREAST CANCER
Funder
National Health and Medical Research Council
Funding Amount
$1,352,322.00
Summary
Cancer cell spread around the body involves changes in the cells which allow them to migrate into blood vessels, travel and then invade other organs, a process called epithelial mesenchymal transition (EMT). EMT also makes cells less sensitive to our best treatments. EMT involves switching on genes that activate these changes and switching off genes that silence them. We will develop therapy that will reverse this process, both reducing cancer spread and making cancer treatment more effective.
Targeting MicroRNA-driven Mesenchymal To Epithelial Transition To Suppress Prostate Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$741,831.00
Summary
Prostate cancer kills ~3,000 men per year in Australia. The development of metastasis is the major cause of prostate cancer-associated death and has limited treatment options. In this study, we will characterise the role of a group of molecules, termed microRNAs, in prostate cancer metastasis. We will also test whether targeting microRNAs using novel drugs termed antagomiRs is an effective strategy to inhibit metastasis and thereby improve prostate cancer mortality.
MicroRNAs are small molecules that modulate the expression of most genes and so affect nearly every biological process and pathology although, they were only discovered in humans less than 10 years ago. The bottleneck in discovering the functions of miRNAs is in identifying their molecular targets, the majority of which remain unknown. We aim to comprehensively identify direct target genes of epithelial-specific microRNAs and to confirm a number of them by gene target validation approaches.
Genetic Programs Orchestrated By AP-1 Transcription Factors In Colorectal Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$599,941.00
Summary
Colorectal cancer (CRC) is the third most common cancer worldwide. About half of all patients diagnosed with the disease die as a result of its spread in the body. This project will investigate the role that a specific DNA-binding protein plays in orchestrating gene expression programs required for CRCs to spread. The research will provide new insights into underlying mechanisms of CRC progression as well as identify new therapeutic targets for aggressive forms of the disease.
Identification Of PACE-1 As A Novel Therapeutic Target For The Treatment Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$606,144.00
Summary
Advanced prostate cancer (PCa) remains the major therapeutic challenge since neither surgery nor systemic therapies are effective at this stage. Recently, we identified a protein called PACE-1 that is essential for PCa cell survival. We plan to investigate the roles of PACE-1 in the development and progression of prostate cancer. We will then test if PACE-1 inactivation alone or in combination with systemic cancer therapies will inhibit prostate tumor growth and disease progression.
Formation And Function Of Circular RNAs In Human Cells
Funder
National Health and Medical Research Council
Funding Amount
$602,906.00
Summary
Circular RNA molecules were recently found to be present in human cells, but their functions are largely unknown.We have discovered that the production of circular RNAs is changed during the differentiation process known as epithelial to mesenchymal transition, which is linked to cancer metastasis. We will investigate the functions of circRNAs, how their formation is controlled, and whether the circRNAs have a role in cancer progression.
The Role Of Angiopoietin-1 In The Self-renewal And Metastasis Of Prostate Cancer Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$558,742.00
Summary
Bone metastasis occurs in more than 80% of cases of advanced prostate cancer (PCa), and is the major cause of morbidity and mortality in PCa patients. Understanding why PCa cells preferentially metastasize to bone may lead to the the development of novel therapy for inhibiting PCa metastasis. This project will study how the bone cell-secreted protein angiopoietin-1 promotes the metastasis of PCa cells to bone and whether inactivation of this protein can inhibit PCa bone metastasis.